Changes in the glycosylation pattern of circulating gonadotropins after acute administration of gonadotropin-releasing hormone in patients with anorexia nervosa

Silvia Savastano, Antonio P Tommaselli, Rossella Valentino, Antonio Luciano, Marianna Gigante, Giacomino Randazzo, Franco Contaldo, Luca Scalfi and Gaetano Lombardi

Department of Molecular and Clinical Endocrinology and Oncology, Experimental Endocrinology and Oncology Center, CNR, Department of Food Science, Department of Experimental and Clinical Medicine, University Federico II, Naples, Italy

(Correspondence should be addressed to S Savastano, Chair of Endocrinology, Department of Molecular and Clinical Endocrinology and Oncology, University Federico II Medical School, via S Pansini 5, 80131 - Naples, Italy)

Abstract
To study the involvement of gonadotropin-releasing hormone (GnRH) in glycosylation of circulating gonadotropin isoforms in anorexia nervosa (AN), 14 amenorrhoic patients with AN, 14 age-matched volunteers in early follicular phase, and five normal-weight re-fed patients with AN were investigated under baseline conditions and after acute administration of GnRH. Plasma gonadotropins were assayed using IRMA before and after concanavalin A affinity chromatography. Baseline plasma gonadotropin levels were lower for both AN and re-fed AN patients than in controls (P<0.005). The increase in FSH and LH after GnRH administration was lower than in controls for AN (P<0.005) and re-fed AN (P<0.005 and P<0.05 respectively) patients. Percentages of total gonadotropin not bound to concanavalin A (complex carbohydrate chains) under baseline conditions were higher in patients with AN than in controls (P<0.005) but decreased after GnRH administration (P<0.001). In re-fed AN patients, the percentage of unbound FSH was higher than in controls (P<0.05), and decreased after GnRH administration (P<0.001), whereas the percentages of unbound LH were not significantly different from controls either before or after GnRH administration. These data suggest that: (a) the acute administration of GnRH induces quantitative and qualitative changes in circulating gonadotropin isoforms in both normal controls and AN patients; (b) during recovery the LH response in re-fed AN patients is associated with a glycosylation pattern that is the same as that for controls.

European Journal of Endocrinology (1998) 138 76–81

Introduction
Anorexia nervosa (AN) is a complex psychiatric disorder, with increasing incidence especially among adolescent and young women, associated with multiple disturbances in central monoaminergic systems and endocrine abnormalities (1). Dysfunctions in the hypothalamus–pituitary–gonadal axis and amenorrhea are common features (2). Although a clear relationship exists between menstrual dysfunction, weight loss and malnutrition, amenorrhea can predate weight loss and may persist despite weight gain (2, 3). An abnormality in the central regulation of the gonadotropin-releasing hormone (GnRH) pulse-generation system has been described in both undernourished animal models (4–6) and humans with AN, with a reduced gonadotropin pulsatility and an age-inappropriate gonadotropin secretion pattern (3, 7–10). Pulsatile GnRH therapy in AN patients has been reported to induce the quantitative restoration of both episodic luteinizing hormone (LH) secretion and pituitary LH responsiveness to GnRH (11). However, the central mechanism underlying diet-induced hypogonadism remains unexplained and persists after the return to a normal diet (1–3, 6, 12).

The microheterogeneity of gonadotropin isoforms is well known in both physiologic and pathologic conditions (13–18). Similarly to thyrotropin-releasing hormone (19–23), a direct effect of GnRH on gonadotropin N-linked carbohydrate branching has been postulated to occur (17–18). Qualitative changes in both circulating follicle-stimulating hormone (FSH) and LH occur in amenorrheic AN patients, with evidence of circulating gonadotropin isoforms that are less sialylated (24). Although the effects of exogenous GnRH administration on gonadotropin isoform distribution pattern have been evaluated in animal models (6, 12) and humans under different conditions (25–28), no studies have been performed on patients with AN to evaluate whether the acute GnRH administration influences circulating gonadotropin glycosylation.

© 1998 Society of the European Journal of Endocrinology
The pattern of elution of plasma gonadotropins from concanavalin A (Con A) was therefore investigated in 14 amenorrhoic patients with AN and five normal-weight re-fed AN patients before and after acute administration of exogenous GnRH in comparison with 14 age-matched normally cycling women.

Materials and methods

Subjects and study procedure

Fourteen hospitalized females, aged 16–27 years, with AN and secondary amenorrhea lasting at least 6 months, and 14 age-matched volunteers of normal weight and with regular menstrual periods, some of whom had already enrolled in our previous study (24), were investigated. The AN patients weighed less than 70% of ideal body weight, with body mass index <17 (normal values (n.v.) 20–25 kg/m²). Ideal body weights were determined from the Metropolitan Life Insurance Co. tables of New York 1983 (29). Five re-fed AN patients, aged 19–31 years with body mass index >20, were included in the study; they had all attained normal eating behavior and a weight greater than 85% of ideal for at least 6 months, and two had resumed regular menstrual periods (three and five menses). All the patients were recruited from the Clinical Nutrition Unit of Federico II University; informed consent had been given in accordance with the Helsinki Declaration. Diagnoses were based on the Diagnostic and Statistical Manual of Mental Disorders (DSM IV) criteria (30). No patient or control was taking any medication known to affect ovary function or had received prior estrogen therapy. Re-fed AN patients and normal controls were evaluated in the precocious follicular phase (4–6 days after the onset of uterine bleeding).

GnRH tests were performed between 0800 and 1000 h after an overnight fast. Blood samples were obtained immediately before and 15, 45, 60 and 90 min after the i.v. injection of 100 μg GnRH (Relisorm L100; Serono, Roma, Italy), via an indwelling antecubital venous catheter. The samples were centrifuged and stored at −80°C until assayed.

RIA

Gonadotropins in both plasma and Con A-affinity column fractions were measured in duplicate using an ultrasensitive IRMA (FSH IRMA CT and LH IRMA CT; Radim, Pomezia, Italy; n.v. 2.5–13 and 1.4–13 IU/l respectively) employing a combination of two monoclonal antibodies: a tube-immobilized β-specific antibody and a labeled one specific for the intact FSH and LH dimers. The sensitivity of the IRMA (level at mean B₀±2.5 S.D.) was 0.1 IU/l for both FSH and LH. The intra-assay coefficients of variation for low and medium values were for FSH 5.1 and 2.7% respectively and for LH 2.8 and 1.5% respectively. Plasma levels of 17β-

estradiol were assayed three times under basal conditions (4–6th day) by RIA using commercial kits (CIS; Tronzano Vercellese, Italy; n.v. 70–220 nmol/l).

Con A affinity chromatography

As previously reported (24), 1 ml aliquots of unextracted serum were added to 3 ml 50% (v/v) agarose-bound Con A (Pharmacia Fine Chemicals, Milan, Italy) in PBS (0.01 mol/l phosphate and 0.15 mol/l NaCl, pH 7.4). They were subsequently placed on 10 ml columns, incubated at room temperature and shaken for 1 h. The FSH and LH fractions that did not bind to Con A (UB) were obtained after centrifugation for 30 min at 1000 g at 4°C. The Con A-bound FSH and LH fractions were obtained using the same buffer containing 300 mmol α-methyl mannopyranoside, with a total recovery of 85–98%. The column fractions were stored at −20°C until immunossayed. Percentages of unbound FSH and LH (% FSH-UB and % LH-UB) were calculated as the ratio of FSH-UB and LH-UB to total FSH and LH concentrations.

Statistical tests

Plasma gonadotropin concentrations were log-transformed before statistical analysis to correct for the heterogeneity of variance. Statistical differences between baseline and post-treatment values were assessed by ANOVA between groups, followed by Newman–Keuls’ test and Student’s unpaired t-test. Differences at P<0.05 were considered statistically significant. Significant relationships between variables were analyzed using Pearson product-moment correlations.

Results

Plasma FSH and LH levels of AN patients (n = 14), re-fed AN patients (n = 5) and controls (n = 14) during baseline and GnRH-stimulated conditions are reported in Table 1. Maximum values for FSH and LH were obtained after 45 min (P<0.001). A significant difference is observed up to 90 min after GnRH administration (P<0.05), except for LH values for AN patients. For FSH and LH, mean values were significantly lower for both AN patients and re-fed AN patients than normal controls under baseline conditions (P<0.005). After acute GnRH challenge, the maximum values for FSH and LH were significantly lower for AN patients than for controls (P<0.005). The maximum FSH and LH values were also significantly lower for re-fed AN patients than for controls, although to a different significance (P<0.005 and P<0.05 respectively).

The mean values of % FSH-UB and % LH-UB before and after GnRH stimulation are reported in Table 2. The minimum values during the test, expressed as mean± S.D., were obtained after 45 min (P<0.001 except for % LH-UB for normal controls and re-fed AN patients and controls).
A significant difference is observed up to 90 min after GnRH administration for both % FSH-UB and % LH-UB for AN patients, and for % FSH-UB only for re-fed AN patients (P<0.001). Under baseline conditions, the % FSH-UB values were significantly higher for both AN and re-fed AN patients than controls (P<0.005). The % LH-UB was also significantly higher in AN patients than controls (P<0.005), while the values for re-fed AN patients did not significantly differ from controls. After acute GnRH challenge, the minimum values for % LH-UB were significantly higher for AN patients than for controls at 45–90 min (P<0.05). No difference was found for % FSH-UB values between the three groups, and for % LH-UB values between re-fed AN patients and controls after 90 min. Therefore for % FSH-UB the significant differences between groups under baseline conditions were no longer evident after the acute GnRH challenge, while for % LH-UB a difference was still present at 45 and 90 min for AN patients, although with a lower significance than under baseline conditions (P<0.05).

Baseline plasma 17β-estradiol levels were significantly lower in AN patients than in re-fed AN patients and normal controls (23.1±4.9 vs 80.9±21.5 and 89.5±16.3 nmol/l respectively).

No significant correlation was observed between either % FSH-UB or % LH-UB and body mass index in AN patients, or between weight, weight gain, and duration of refeeding in re-fed AN patients. A weak negative correlation was found in normal controls between maximum FSH values and minimum % FSH-UB values at 45 min (r = -0.6).

**Discussion**

We previously found a significant increase in the percentage of FSH and LH molecules not retained on Con A (complex-type asparagine-linked oligosaccharides) in a group of amenorrhoic AN patients than in eumenorrhoic normal-weight controls, and we related this alteration to a decrease in gonadotropin bioactivity (24). In the present experiment, we have shown that, in spite of low plasma concentrations of stimulated gonadotropin, the glycosylation pattern of gonadotropins in AN patients is modified immediately after an acute GnRH challenge. In particular, in accord with previous reports (26, 27, 31), in normal controls a single acute GnRH dose significantly decreases % FSH-UB 45 min after GnRH injection, without any further decrease in the naturally occurring secretion of

### Table 1 Plasma FSH and LH concentrations after an acute challenge with 100 μg GnRH.

<table>
<thead>
<tr>
<th>Time after GnRH (min)</th>
<th>NC</th>
<th>AN</th>
<th>Re-fed AN</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Plasma FSH (IU/l)</td>
<td>Plasma LH (IU/l)</td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>8.7</td>
<td>2.0b</td>
<td>4.1b</td>
</tr>
<tr>
<td></td>
<td>(6.5, 12.0)</td>
<td>(2.0, 5.8)</td>
<td>(1.9, 11.6)</td>
</tr>
<tr>
<td>15</td>
<td>12.2</td>
<td>4.0</td>
<td>7.1</td>
</tr>
<tr>
<td></td>
<td>(7.6, 20.9)</td>
<td>(2.9, 12.5)</td>
<td>(2.6, 23.4)</td>
</tr>
<tr>
<td>45</td>
<td>17.7a</td>
<td>9.0*a,b</td>
<td>12.7a,b</td>
</tr>
<tr>
<td></td>
<td>(11.8, 24.1)</td>
<td>(4.9, 20.4)</td>
<td>(5.6, 29.3)</td>
</tr>
<tr>
<td>90</td>
<td>14.8d</td>
<td>8.5d</td>
<td>9.5d</td>
</tr>
<tr>
<td></td>
<td>(9.2, 24.3)</td>
<td>(5.0, 17.1)</td>
<td>(6.9, 13.3)</td>
</tr>
</tbody>
</table>

Values are geometric means and their 95% confidence limits for the concentrations. NC, normal controls (n = 14); AN, patients with AN (n = 14); Re-fed AN, normal-weight re-fed AN patients (n = 5).

* Maximum value during the test.

### Table 2 Percentage of Unbound FSH and LH fractions (UB) after an acute challenge with 100 μg GnRH. Values are means ± SD.

<table>
<thead>
<tr>
<th>Time after GnRH (min)</th>
<th>NC</th>
<th>AN</th>
<th>Re-fed AN</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Plasma FSH (IU/l)</td>
<td>Plasma LH (IU/l)</td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>80.5 ± 9.3</td>
<td>96.7 ± 7.7b</td>
<td>95.3 ± 21b</td>
</tr>
<tr>
<td></td>
<td>(71.5, 120)</td>
<td>(60.7, 5.8)</td>
<td>(78.6, 11.6)</td>
</tr>
<tr>
<td>15</td>
<td>71.7 ± 9.7</td>
<td>70.5 ± 17.2</td>
<td>75.6 ± 8.3</td>
</tr>
<tr>
<td></td>
<td>(65.2, 11.7a)</td>
<td>(57.0, 11.4a)</td>
<td>(65.3, 7.4a)</td>
</tr>
<tr>
<td>45</td>
<td>74.6 ± 9.2</td>
<td>64.1 ± 15.3</td>
<td>68.2 ± 6.2a</td>
</tr>
<tr>
<td></td>
<td>(68.5, 24.3)</td>
<td>(50.0, 17.1)</td>
<td>(6.9, 13.3)</td>
</tr>
</tbody>
</table>

NC, normal controls (n = 14); AN, patients with AN (n = 14); Re-fed AN, normal-weight re-fed AN patients (n = 5).

* Minimum value during the test.

* P < 0.001 vs baseline; b P < 0.005 vs NC; c P < 0.05 vs NC; d P < 0.05 vs baseline.
baseline unbound LH isoforms. Conversely, in AN patients, a single acute GnRH dose significantly reduces the abnormally high percentage of unbound FSH and LH 45 min after GnRH injection, so that for FSH-UB the significant baseline differences between AN patients and controls are no longer evident, whereas for LH-UB they are still present, although to a lower significance than under baseline conditions. In other words, the intrapituitary gonadotropin pools of patients with AN contain higher amounts of mannose-rich less-sialylated molecules after acute GnRH administration than before, and these higher concentrations are the same as baseline concentrations in control subjects in the follicular phase, as previously reported to occur in thyrotropin secretion after thyrotropin-releasing hormone administration (19–21, 32). In AN, changes in the percentage of unbound FSH and LH are still evident 90 min after GnRH administration, whereas in normal controls the percentage of unbound FSH returned to baseline values. This may be related to a relative impairment of the unstimulated pituitary to process the gonadotropin molecules to more mature isoforms, as also described for thyrotropin (19, 20). Conversely, in normal controls, also taking into account the selective survival of serum isoforms, the secretion of all available isoforms follows the initial preferential release of bound isoforms 90 min after GnRH. As naturally occurring FSH contains more complex-type oligosaccharide chains than LH (31), the effect of GnRH appears to be more striking on LH than on FSH, particularly for AN patients.

Similarly to AN patients, re-fed AN patients exhibit higher % FSH-UB values than normal controls, with a significant decrease after GnRH administration; however, neither baseline nor stimulated % LH-UB values were significantly different from normal controls. This suggests that, in normal-weight re-fed AN patients, the increase in basal plasma levels of estrogen is related to the secretion of LH isoforms that are not different from those of control subjects in the follicular phase, probably because of restoration of the endogenous GnRH pulse frequency. In this context, the changes in baseline and stimulated LH glycoisoforms in re-fed AN patients may provide a possible additional marker for the prediction of the reversal of endocrine abnormalities.

The microheterogeneity of pituitary and circulating gonadotropin isoforms appears to be related to the endocrine milieu (18). In particular, GnRH (25–27, 33) and estrogens (12, 34–39) have been proposed to be physiologic modulators of gonadotropin polymorphism. Although a direct estrogen effect on the glycosylation pattern of gonadotropins in AN patients. In re-fed AN patients, the effect of GnRH may be related to weight gain and increase in estrogens. In AN, however, we cannot infer that the GnRH effect is mediated through estrogenic influences, as changes in gonadotropin isoforms are also observed in the presence of low estrogen concentrations without interference from estrogen replacement therapy. Finally, the involvement of ovarian factors other than sex steroids, such as inhibin, activin and follistatin, cannot be excluded from the present study.

Although further evidence obtained with a larger group of patients is required to confirm this hypothesis, our data suggest that, as far as patients with AN are concerned, nutritional state, body fat increase, GnRH and estrogen concentrations are presumably only cofactors in the pathogenesis of amenorrhea. This hypothesis is in line with neuroendocrine dysregulation of gonadotropin secretion in AN being part of the overall alteration of the monoaminergic neurotransmission underlying the eating behaviour disturbances. In conclusion, AN patients provide a suitable and original model for evaluating the effects in vivo of GnRH administration upon gonadotropin glycosylation pattern. In these patients, the abnormalities in glycosylation of gonadotropin isoforms are reversed by acute GnRH administration. The contribution of chronic energy deprivation during refeeding needs to be further investigated.

Acknowledgements

The authors are very grateful to the ‘Gruppo di Studio in Endocrinologia’ (G.S.E., Naples, Italy) for financial support.
References


37 Wide L & Naessén T. 17β-Oestradiol counteracts the formation of the more acidic isoforms of follicle-stimulating hormone and luteinizing hormone after menopause. *Clinical Endocrinology* 1994 40 783–789.


Received 21 April 1997
Accepted 26 August 1997